Clinical Trials - January 13, 2020
Neurovive completes recruitment in Phase 1a/b study
NeuroVive Pharmaceutical has announced the completed recruitment of healthy volunteers in the second part of the company’s ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chronic oral treatment of primary mitochondrial disease. The first part of the study, in which the effect of food intake on the uptake of KL1333 after a […]
Financing - March 11, 2019
NeuroVive raises 28.2 million SEK
The company has successfully conducted a directed new issue of shares, which has raised proceeds to NeuroVive of SEK 28.2 million before issue costs. These proceeds will be used primarily to accelerate clinical development activities, states the company in their press release. The investors are reputable Swedish and international investors led by Nyenburgh Investment Partners, […]
Clinical Trials - December 11, 2017
Promising results from NeuroVive
NeuroVive Pharmaceutical and Yungjin Pharm announces that the phase I clinical study in Korea within the companies’ joint project KL1333, an investigational treatment for genetic mitochondrial disorders, including MELAS (Mitochondrial Myopathy, Encephalopahty, Lactic Acidosis and Stroke-like episodes), is proceeding according to plan. The first part of the study has been successful. The pharmacokinetic data was […]
Collaboration - November 11, 2017
NeuroVive collaborates with Lund University
NeuroVive Pharmaceutical and Ramin Massoumi at Lund University have been granted 2,5 MSEK from the Swedish Foundation for Strategic Research (SFF) for an Industrial PhD to study the role of cyclophilins in liver cancer. The research will be done within NeuroVive’s project NVP024, which is focused on the development of a novel liver cancer treatment. The overall objective of […]
In a new job - September 5, 2017
New Vice President at NeuroVive
NeuroVive Pharmaceutical has appointed Mark Farmery as Vice President Business Development. Dr Farmery will report to CEO Erik Kinnman and will join the company’s management team. The appointment strengthens and expands the team in a critical area and is in line with NeuroVive’s dual business model, which focuses on early phase projects for out-licensing at […]
Financing - June 7, 2017
NeuroVive receives research grant
The company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseases. NeuroVive receives the grant from Vinnova’s 2017 Swelife call to continue progressing the preclinical project NVP015. The cutting edge NVP015 project is aimed at developing a new pharmacological treatment […]
